The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of BPM 31510 in advanced solid tumors: Updated analysis of a novel treatment with promising activity.
Andrew Eugene Hendifar
No relevant relationships to disclose
Sant P. Chawla
No relevant relationships to disclose
Doris Quon
No relevant relationships to disclose
Victoria S Chua
No relevant relationships to disclose
Lita Fernandez
No relevant relationships to disclose
Sandeep Nagre
No relevant relationships to disclose
Marita Okunnu
No relevant relationships to disclose
Bartosz Chmielowski
No relevant relationships to disclose
Arun S. Singh
No relevant relationships to disclose
Slava Akmaev
Employment or Leadership Position - Berg Pharma
Stock Ownership - Berg Pharma
David Chatman
Employment or Leadership Position - Berg Pharma
Stock Ownership - Berg Pharma
John McCook
Employment or Leadership Position - Berg Pharma
Stock Ownership - Berg Pharma
Shen Luan
Employment or Leadership Position - Berg Pharma
Stock Ownership - Berg Pharma
Rangaprasad Sarangarajan
Employment or Leadership Position - Berg Pharma
Stock Ownership - Berg Pharma
Paul Y. Song
Employment or Leadership Position - Berg Pharma
Stock Ownership - Berg Pharma
Niven R Narain
Employment or Leadership Position - Berg Pharma
Stock Ownership - Berg Pharma